Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Inclusion Criteria: * Histologic diagnosis of nasopharyngeal carcinoma * Distance metastasis at least 6 months after radical treatment * Not suitable for local treatment, e.g. surgery, TACE * At least one measurable lesion * Estimate survival \>3months * Range from 18～70 years old * PS 0\~1 * WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L * ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN * 0Serum creatinine \< 1.5×ULN Exclusion Criteria: * Central nervous system metastases * Suitable for local treatment * Second malignancy within 5 years * Precious therapy with an investigational agent * Uncontrolled seizure disorder or other serious neurologic disease * ≥ Grade Ш allergic reaction to any drug including in this study * Clinically significant cardiac or respiratory disease * Creatinine clearance \< 30ml/min * Drug or alcohol addition * Do not have full capacity for civil acts * Severe complication, active infection * Concurrent immunotherapy or hormone therapy for other diseases * Pregnancy or lactation